Literature DB >> 12913698

Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma.

Monica Ricote1, Mar Royuela, Ignacio García-Tuñón, Fermín R Bethencourt, Ricardo Paniagua, Benito Fraile.   

Abstract

PURPOSE: Tumor necrosis factor-alpha (TNF-alpha) exerts apoptosis throughout an intracellular transduction pathway that involves the protein kinases TRAF-2 (integration point of apoptotic and survival signals), signal regulating kinase (ASK-1) (pro-apoptotic protein), mitogen activated protein kinase-kinase 4 (MEK-4) (p38 activator and metastasis suppressor gene), Jun N-terminal kinase (JNK) (stress mitogen activated protein kinase) and the transcription factor activator protein-1 (AP-1).
MATERIALS AND METHODS: Biopsies from 20 normal, 35 hyperplastic and 27 carcinomatous human prostates were obtained for immunohistochemical and Western blot studies of the mentioned TNF-alpha/AP-1 transduction pathway members.
RESULTS: In normal prostates immunoreactions to TRAF-2, ASK-1, MEK-4 and JNK were positive, while no immunoreaction to AP-1 was detected. Although in benign prostatic hyperplasia the percent of immunostained specimens and intensity of immunoreactions to TRAF-2, ASK-1, MEK-4 and JNK decreased, the immunoreaction to AP-1 was positive in 27.3%. In most carcinomatous specimens the immune reaction was negative for all proteins of the TRAF-2/AP-1 pathway.
CONCLUSIONS: The TNF-alpha/AP-1 pathway might be a response to the excessive proliferative stimulus, although this response seems to be insufficient to counteract extracellular signals of cell proliferation. In prostate cancer this pathway is probably inactivated by other factors, such as p21 (at the ASK-1 level) or bcl-2 (at the JNK level).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913698     DOI: 10.1097/01.ju.0000082712.41945.17

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

2.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Authors:  Hari K Koul; Mantu Pal; Sweaty Koul
Journal:  Genes Cancer       Date:  2013-09

4.  Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.

Authors:  Brian W C Tse; Kieran F Scott; Pamela J Russell
Journal:  Prostate Cancer       Date:  2012-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.